Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.63 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4760134 | 0.98 | CASP2 (0.66) | CASP2NAAAEPHX2MEN1KMT2A | |
| SCHEMBL6569733 | 0.96 | CASP2 (0.63) | CASP2NAAAEPHX2MEN1KMT2A | |
| SCHEMBL17753990 | 0.94 | CASP2 (0.66) | CASP2NAAAEPHX2MEN1KMT2A | |
| SCHEMBL4760086 | 0.89 | CASP2 (0.58) | CASP2NAAAEPHX2MEN1KMT2A | |
| SCHEMBL18139443 | 0.87 | CASP2 (0.61) | CASP2NAAAEPHX2FAAHALDH1A1 | |
| SCHEMBL6569046 | 0.87 | CASP2 (0.56) | CASP2NAAAEPHX2MEN1KMT2A | |
| SCHEMBL11396166 | 0.86 | CASP2 (0.59) | CASP2NAAAEPHX2MEN1KMT2A | |
| SCHEMBL18140129 | 0.86 | CASP2 (0.65) | CASP2NAAAEPHX2FAAHALDH1A1 | |
| SCHEMBL18141705 | 0.86 | CASP2 (0.65) | CASP2NAAAEPHX2FAAHALDH1A1 | |
| SCHEMBL18140026 | 0.86 | CASP2 (0.65) | CASP2NAAAEPHX2FAAHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6265437-B1 | ALCOHOLISM | LIPHA (FR) | 2001-07-24 | — | — | US | claimed |
| CN-1182837-C | Orally administrable immediate and prolonged-release Galenic form comprising absorption-promoting agent and use of this absorption-promoting agent | Ĭ��ר���ɷ�����˾ | 2005-01-05 | — | — | CN | disclosed |
| EP-1056445-B1 | ORALLY ADMINISTRABLE IMMEDIATE-RELEASE AND PROLONGED-RELEASE GALENIC FORM COMPRISING AN ABSORPTION-PROMOTING AGENT AND USE OF THIS ABSORPTION-PROMOTING AGENT | MERCK PATENT GMBH (DE) | 2004-06-02 | — | — | EP | disclosed |
| EP-1410791-A1 | Orally administrable galenic form comprising metformine and an absorption-promoting agent | MERCK PATENT GmbH (DE) | 2004-04-21 | — | — | EP | disclosed |
| US-6514524-B1 | Improved absorption of hydrophilic ingredients because of particular excipients; calcium 3-acetylamino-1-propane sulfonate (calcium acamprosate); polysorbates, fatty ethers or esters of PEG, polyglycolysed glycerides | MERCK PATENTGESELLSCHAFT MIT (DE) | 2003-02-04 | — | — | US | disclosed |
| US-6426087-B1 | GALENIC FORMS; SUSTAINED RELEASE | MERCK PATENT GESELLSCHAFT MIT (DE) | 2002-07-30 | — | — | US | disclosed |
| US-6265437-B1 | ALCOHOLISM | LIPHA (FR) | 2001-07-24 | — | — | US | disclosed |